|
Press Releases |
|
 |
|
Wednesday, April 9, 2025 |
|
SinoMab BioScience Limited Breakthrough Phase 1b POC Results for SM17 in Atopic Dermatitis |
SinoMab BioScience Limited (Stock Code: 3681.HK, "SinoMab" or the "Company"), is pleased to announce our breakthrough topline results from the completed Phase 1b clinical study evaluating SM17, a novel investigational therapy targeting the IL-25 (IL-17E) receptor pathway in moderate to severe atopic dermatitis (AD). more info >> |
|
中國抗體製藥有限公司SM17治療特應性皮炎1b期概念驗證臨床試驗取得突破性結果 |
中國抗體製藥有限公司(「中國抗體」或「本公司」;股份代號:3681)宣佈,其SM17針對中重度特應性皮炎(AD)的創新療法已完成1b期臨床研究,並獲得突破性頂線數據結果。 more info >> |
|
中国抗体制药有限公司SM17治疗特应性皮炎1b期概念验证临床试验取得突破性结果 |
中国抗体制药有限公司(“中国抗体”或“本公司”;股份代号:3681)宣布,其SM17针对中重度特应性皮炎(AD)的创新疗法已完成1b期临床研究,并获得突破性顶线数据结果。 more info >> |
|
Tuesday, April 16, 2024 |
|
中国抗体SM17治疗特应性皮炎(AD)之临床前结果刊登于国际科学期刊《Allergy》 |
more info >> |
|
中國抗體SM17治療特應性皮炎(AD)之臨床前結果刊登於國際科學期刊《Allergy》 |
more info >> |
|
SinoMab BioScience preclinical results of SM17 on atopic dermatitis (AD) published on International Scientific Journal Allergy |
SinoMab BioScience announced preclinical results of SM17 on atopic dermatitis (AD) published on International Scientific Journal Allergy. more info >> |
|
Tuesday, September 12, 2023 |
|
中国抗体SM17新药研究申请再获国家药监局批准 |
专注研究、发展、制造及商业化免疫性疾病疗法的香港生物制药公司—中国抗体制药有限公司(上市编号:3681.HK,下称“中国抗体”或“本公司”)欣然宣布,本公司所提交之治疗特应性皮炎(“AD”)的同类首创(First-in-Class)治疗产品SM17的新药研究申请(“新药研究申请”) more info >> |
|
中國抗體SM17新藥研究申請再獲國家藥監局批准 |
專注研究、發展、製造及商業化免疫性疾病療法的香港生物製藥公司—中國抗體製藥有限公司(上市編號:3681.HK,下稱「中國抗體」或「本公司」)欣然宣佈,本公司所提交之治療特應性皮炎(「AD」)的同類首創(First-in-Class)治療產品SM17的新藥研究申請(「新藥研究申請」) more info >> |
|
SinoMab's IND Application of SM17 has once again Received Approval from NAMP |
A Hong Kong-based biopharmaceutical company dedicated to the research, development, manufacturing and commercialisation of therapeutics for the treatment of immunological diseases- SinoMab BioScience Limited (Stock Code: 3681.HK, "SinoMab" or the "Company") more info >> |
|
Monday, August 14, 2023 |
|
中国抗体SM17针对治疗哮喘疾病的新药研究申请获国家药监局批准 |
专注研究、发展、制造及商业化免疫性疾病疗法的香港生物制药公司—中国抗体制药有限公司(上市编号:3681.HK,下称“中国抗体”或“本公司”)欣然宣布,本公司所提交之治疗哮喘的同类首创(First-in-Class)治疗产品SM17的新药研究申请(“新药研究申请”)于2023年8月11日获中国国家药品监督管理局(“国家药监局”)批准。 more info >> |
|
|
|
|
|
|
|
|
Latest Press Releases |
|
Theinvestmedia.com Offers Exclusive Brokerage Account Opening Offers and In-Depth Tutorials, Empowering Investors with Precise Decision-Making
Jul 26, 2025 08:00 HKT/SGT
|
|
|
Theinvestmedia.com 提供独家开户优惠与深度教学,赋能投资者精准决策
Jul 26, 2025 08:00 HKT/SGT
|
|
|
Theinvestmedia.com 提供獨家開戶優惠與深度教學,賦能投資者精準決策
Jul 26, 2025 08:00 HKT/SGT
|
|
|
maxWin Receives Honesty Award 2025, Setting New Standards for Integrity in Online Gaming
Jul 25, 2025 20:00: JST
|
|
|
維立志博於聯交所主板成功上市
Jul 25, 2025 19:36 HKT/SGT
|
|
|
maxWin Receives Honesty Award 2025, Setting New Standards for Integrity in Online Gaming
Jul 25, 2025 19:00 HKT/SGT
|
|
|
维立志博于联交所主板成功上市
Jul 25, 2025 18:00 HKT/SGT
|
|
|
OMS Energy Recorded Significant Profits Growth in 2025FY, Roth Capital Rating it "Buy" with a Potential 40% Upside TP
Jul 25, 2025 17:18 HKT/SGT
|
|
|
OMS能源2025財年業績增長強勁 Roth Capital評級買入潛在升幅40%
Jul 25, 2025 17:18 HKT/SGT
|
|
|
OMS能源2025财年业绩增长强劲 Roth Capital评级买入潜在升幅40%
Jul 25, 2025 17:18 HKT/SGT
|
|
|
百仕達(1168)擬更名「Z Fin Limited」控股股東換股以行動彰顯信心和支持 轉型戰略升級前景看俏
Jul 25, 2025 17:03 HKT/SGT
|
|
|
百仕达(1168)拟更名“Z Fin Limited” 控股股东换股以行动彰显信心和支持 转型战略升级前景看俏
Jul 25, 2025 17:03 HKT/SGT
|
|
|
CWE held 'Lancang Mekong Green Course' Open Day to celebrate the 10th anniversary of the Nam Ngiep 2 Hydropower Station
Jul 25, 2025 16:25 HKT/SGT
|
|
|
Olympus Enters Strategic Partnership to Develop Endoluminal Gastrointestinal Robotics
Jul 25, 2025 16:00 JST
|
|
|
Eisai Listed for 24th Consecutive Year in FTSE4Good Index Series, an Index for Socially Responsible Investment
Jul 25, 2025 13:31 JST
|
|
|
|
More News >> |
|
|
|
|
|